Preoperative angiotensin-converting enzyme inhibition can cause severe post CPB vasodilation - Current UK opinion

Asian Cardiovascular and Thoracic Annals

Volumn 12, Issue 4, 2004, Pages 346-349

  Devbhandari, Mohan P ^a,b   Balasubramanian, Sendhil K ^a   Codispoti, Max ^a   Nzewi, Onyekwelu C ^a   Prasad, Sai U ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INFUSION FLUID; INOTROPIC AGENT; VASOCONSTRICTOR AGENT;

ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; MEDICAL LITERATURE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SURGEON; UNITED KINGDOM; VASODILATATION;

EID: 10444232734     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230401200414     Document Type: Article

References (12)

1. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
2. Mansoor AM, Honda M, Kuramochi T, Kanaka K, Morioka S, Takabatake T. Effects of ACE inhibition and beta-blockade on collagen-remodelling in the heart of Bio14.6 hamsters. Clin Exp Parmacol Physiol 1996;23:43-9.
3. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
4. Patten RD, Kronenberg MW, Benedict CR, Udelson JE, Kinan D, Stewart D, et al. Acute and long term effects of the angiotensin converting enzyme inhibitor enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. Am Heart J 1997;134:37-43.
5. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD. Angiotensin converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anaesth Analg 1995;80:437-9.
6. Ruiz Ros JA, Ortega VV, Martinez JA, Tovar I, Nuno JA, Florenciano R, et al. Stunned myocardium and cellular damage in patients undergoing valvular cardiac surgery and pretreated with captoril. J Cardiovasc Surg (Torino) 1999;40:203-10.
7. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-80.
8. Taggart DP. Effect of omitting regular ACE inhibitor medication before cardiac surgery on hemodynamic variables and vasoactive drug requirements. Br J Anaesth 2000;84:693-4.
9. Rady MY, Ryan T. The effects of preoperative therapy with angiotensin-converting enzyme inhibitors on clinical outcome after cardiovascular surgery. Chest 1998;114:487-94.
10. Licker M, Neidhart P, Lustenberger S, Valloton MB, Kalonji T, Fathi M, et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anaesthesiology 1996;84:789-800.
11. Webb CM, Underwood R, Anagnostopoulos C, Bennett JG, Pepper J, Lincoln C, et al. The effect of angiotensin converting enzyme inhibition on myocardial function and blood pressure after coronary artery bypass surgery - a randomised study. Eur J Cardiothorac Surg 1998;13:42-8.
12. Pigott DW, Nagle C, Allman K, Westaby S, Evans RD. Effect of omitting regular ACE inhibitor medication before cardiac surgery on hemodynamic variables and vasoactive drug requirements. Br J Anaesth 2000;83:715-20.